Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price […]
